Collaboration aims to improve trial planning and expand patient access to biomarker-matched studies in AustraliaHighlights Collaboration aims to accelerate precision oncology research in AustraliaCombines Fortrea’s experience in oncology clinical trials with Omico’s Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) programTogether, Fortrea and Omico offer more efficient investigator site selection and faster patient access by connecting patients with relevant biomarker-driven clinica ...